|
1.
|
Jemal A, Siegel R, Ward E, Murray T, Xu J
and Thun MJ: Cancer statistics, 2007. CA Cancer J Clin. 57:43–66.
2007. View Article : Google Scholar
|
|
2.
|
Levi F, La Vecchia C, Randimbison L and
Franceschi S: Incidence of infiltrating cancer following
superficial bladder carcinoma. Int J Cancer. 55:419–554. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Black PC and Dinney CP: Bladder cancer
angiogenesis and metastasis - translation from murine model to
clinical trial. Cancer Metastasis Rev. 26:623–634. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Matrisian LM: Metalloproteinases and their
inhibitors in matrix remodeling. Trends Genet. 6:121–125. 1990.
View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Liotta LA: Tumor invasion and
metastasis-role of extracellular matrix: Rhoads Memorial Award
Lecture. Cancer Res. 46:1–7. 1986.PubMed/NCBI
|
|
6.
|
Bond M, Rosalind P, Fabunmi P, Baker AH
and Newby AC: Synergistic upregulation of metalloproteinase-9 by
growth factors and inflammatory cytokines: an absolute requirement
for transcription factor NF-kappa B. FEBS Lett. 435:29–34. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Sato H and Seiki M: Regulatory mechanism
of 92 kDa type IV collagenase gene expression which is associated
with invasiveness of tumor cells. Oncogene. 8:395–405.
1993.PubMed/NCBI
|
|
8.
|
Lee SJ, Cho SC, Lee EJ, Kim S, Lee SB, Lim
JH, Choi YH, Kim WJ and Moon SK: Interleukin-20 promotes migration
of bladder cancer cells through extracellular signal-regulated
kinase (ERK)-mediated MMP-9 protein expression leading to nuclear
factor (NF-κB) activation by inducing the up-regulation of
p21(WAF1) protein expression. J Biol Chem. 288:5539–5552.
2013.PubMed/NCBI
|
|
9.
|
Moon SK, Cha BY and Kim CH: ERK1/2
mediates TNF-alpha-induced matrix metalloproteinase-9 expression in
human vascular smooth muscle cells via the regulation of NF-kappaB
and AP-1: involvement of the ras dependent pathway. J Cell Physiol.
198:417–427. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Sato H, Kita M and Seiki M: v-Src
activates the expression of 92-kDa type IV collagenase gene through
the AP-1 site and the GT box homologous to retinoblastoma control
elements. A mechanism regulating gene expression independent of
that by inflammatory cytokines. J Biol Chem. 268:23460–23468.
1993.PubMed/NCBI
|
|
11.
|
Nicosia SV, Bai W, Cheng JQ, Coppola D and
Kruk PA: Oncogenic pathways implicated in ovarian epithelial
cancer. Hematol Oncol Clin North Am. 17:927–943. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Cho A, Graves J and Reidy MA:
Mitogen-activated protein kinases mediate matrix
metalloproteinase-9 expression in vascular smooth muscle cells.
Arterioscler Thromb Vasc Biol. 20:2527–2532. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Yao J, Xiong S, Klos K, Nguyen N, Grijalva
R, Li P and Yu D: Multiple signaling pathways involved in
activation of matrix metalloproteinase-9 (MMP-9) by heregulin-beta1
in human breast cancer cells. Oncogene. 20:8066–8074. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Kittipatarin C and Khaled AR: Interlinking
interleukin-7. Cytokine. 39:75–83. 2007. View Article : Google Scholar
|
|
15.
|
Jiang Q, Li WQ, Aiello FB, Mazzucchelli R,
Asefa B, Khaled AR and Durum SK: Cell biology of IL-7, a key
lymphotrophin. Cytokine Growth Factor Rev. 16:513–533. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Mian BM, Dinney CP, Bermejo CE, Sweeney P,
Tellez C, Yang XD, Gudas JM, McConkey DJ and Bar-Eli M: Fully human
anti-interleukin 8 antibody inhibits tumor growth in orthotopic
bladder cancer xenografts via down-regulation of matrix
metal-loproteases and nuclear factor-kappaB. Clin Cancer Res.
9:3167–3175. 2003.PubMed/NCBI
|
|
17.
|
Sier CF, Casetta G, Verheijen JH, Tizzani
A, Agape V, Kos J, Blasi F and Hanemaaijer R: Enhanced urinary
gelatinase activities (matrix metalloproteinases 2 and 9) are
associated with early-stage bladder carcinoma: a comparison with
clinically used tumor markers. Clin Cancer Res. 6:2333–2340.
2000.
|
|
18.
|
Davies B, Waxman J, Wasan H, Abel P,
Williams G, Krausz T, Neal D, Thomas D, Hanby A and Balkwill F:
Levels of matrix metalloproteases in bladder cancer correlate with
tumor grade and invasion. Cancer Res. 53:5365–5369. 1993.PubMed/NCBI
|
|
19.
|
Nutt JE, Durkan GC, Mellon JK and Lunec J:
Matrix metalloproteinases (MMPs) in bladder cancer: the induction
of MMP9 by epidermal growth factor and its detection in urine. BJU
Int. 91:99–104. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Moses MA, Wiederschain D, Loughlin KR,
Zurakowski D, Lamb CC and Freeman MR: Increased incidence of matrix
metalloproteinases in urine of cancer patients. Cancer Res.
58:1395–1399. 1998.PubMed/NCBI
|
|
21.
|
Di Carlo A, Terracciano D, Mariano A and
Macchia V: Urinary gelatinase activities (matrix metalloproteinases
2 and 9) in human bladder tumors. Oncol Rep. 15:1321–1326.
2006.PubMed/NCBI
|
|
22.
|
Fleming HE and Paige CJ: Pre-B cell
receptor signaling mediates selective response to IL-7 at the pro-B
to pre-B cell transition via an ERK/MAP kinase-dependent pathway.
Immunity. 15:521–531. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Crawley JB, Rawlinson L, Lali FV, Page TH,
Saklatvala J and Foxwell BM: T cell proliferation in response to
interleukins 2 and 7 requires p38MAP kinase activation. J Biol
Chem. 272:15023–15027. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Reddy KB, Nabha SM and Atanaskova N: Role
of MAP kinase in tumor progression and invasion. Cancer Metastasis
Rev. 22:395–403. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Li WQ, Jiang Q, Aleem E, Kaldis P, Khaled
AR and Durum SK: IL-7 promotes T cell proliferation through
destabilization of p27Kip1. J Exp Med. 203:573–582. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Barata JT, Cardoso AA, Nadler LM and
Boussiotis VA: Interleukin-7 promotes survival and cell cycle
progression of T-cell acute lymphoblastic leukemia cells by
down-regulating the cyclin-dependent kinase inhibitor p27(kip1).
Blood. 98:1524–1531. 2001. View Article : Google Scholar
|
|
27.
|
Hofmeister R, Khaled AR, Benbernou N,
Rajnavolgyi E, Muegge K and Durum SK: Interleukin-7: physiological
roles and mechanisms of action. Cytokine Growth Factor Rev.
10:41–60. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Coussens LM and Werb Z: Inflammation and
cancer. Nature. 420:860–867. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Dranoff G: Cytokines in cancer
pathogenesis and cancer therapy. Nat Rev Cancer. 4:11–22. 2004.
View Article : Google Scholar
|
|
30.
|
Goswami B, Rajappa M, Sharma M and Sharma
A: Inflammation: its role and interplay in the development of
cancer, with special focus on gynecological malignancies. Int J
Gynecol Cancer. 18:591–599. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Loda M, Cukor B, Tam SW, Lavin P,
Fiorentino M, Draetta GF, Jessup JM and Pagano M: Increased
proteasome-dependent degradation of the cyclin-dependent kinase
inhibitor p27 in aggressive colorectal carcinomas. Nat Med.
3:231–234. 1997. View Article : Google Scholar
|
|
32.
|
Catzavelos C, Bhattacharya N, Ung YC,
Wilson JA, Roncari L, Sandhu C, Shaw P, Yeger H, Morava-Protzner I,
Kapusta L, Franssen E, Pritchard KI and Slingerland JM: Decreased
levels of the cell-cycle inhibitor p27Kip1 protein: prognostic
implications in primary breast cancer. Nat Med. 3:227–230. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Shariat SF, Zlotta AR, Ashfaq R,
Sagalowsky AI and Lotan Y: Cooperative effect of cell-cycle
regulators expression on bladder cancer development and biologic
aggressiveness. Mod Pathol. 20:445–459. 2007. View Article : Google Scholar : PubMed/NCBI
|
